573
Participants
Start Date
May 14, 2013
Primary Completion Date
February 29, 2016
Study Completion Date
July 5, 2019
Regorafenib (Stivarga, BAY73-4506)
Regorafenib, 40 mg tablets
Placebo
Placebo tablets matching in appearance
Taoyuan District
Vienna
Bruxelles - Brussel
Budapest
Camperdown
Liverpool
Bern
Box Hill
Clayton
Linz
Herston
Debrecen
Bellinzona
La Louvière
Kaposvár
Graz
Taipei
New York
Turin
Taipei
Marseille
Berlin
Córdoba
Rochester
Pittsburgh
Genoa
Milan
Milan
Hamburg
Dijon
Richmond
Bergamo
Madrid
Madrid
Madrid
Novara
Hanover
Toulouse
Oviedo
Tampa
Montpellier
Rennes
Padua
La Tronche
Magdeburg
Bologna
Louisville
Modena
Essen
Angers
Busan
Zaragoza
Cologne
Reims
Aachen
Vandœuvre-lès-Nancy
Mainz
Minneapolis
Pisa
Lille
Frankfurt am Main
Chicago
St Louis
Perpignan
Lyon
Heidelberg
Foggia
Paris
Paris
Aurora
Napoli
München
Kaohsiung City
Los Angeles
Los Angeles
Clichy
Créteil
Villejuif
Seattle
Beijing
Beijing
Beijing
Beijing
Dalian
Singapore
Moscow
Harbin
Shanghai
Shanghai
Shanghai
Nanjing
Suzhou
Hefei
Tianjin
Fuzhou
Chongqing
Changsha
Wuhan
Guangzhou
Guangzhou
Guangzhou
Nanning
Chengdu
Barnaul
Xi'an
Xi'an
Xi'an
Orange
Washington D.C.
Gainesville
Worcester
Pilar
Salvador
São Paulo
Hradec Králové
Olomouc
Prague
Caen
Nice
Rome
Cagliari
Chiba
Kashiwa-shi
Fukuoka
Iizuka-shi
Yokohama
Kumamoto
Osaka
Osakasayama-shi
Utsunomiya
Chiyoda-ku
Chuo-ku
Musashino-shi
Amsterdam
Leiden
Moscow
Daegu
Seoul
Seoul
Alicante
Barcelona
Barcelona
Birmingham
Leeds
Bristol
London
London
Lead Sponsor
Bayer
INDUSTRY